QuorumCivic. Hidden in plain sight Get the app
Bill intelligence

Congress subsidizes infant formula makers—with no guarantee prices will drop

H.R. 2008 — Infant Formula Made in America Act of 2025 · Filed by Zachary (Zach) Nunn (R-IA) · 5 cosponsors · Introduced Mar 10, 2025 · Referred to committee

65%
Transparency
Typical bill: 82%
25/100
Hidden-provision risk
Typical bill: 15/100
Infant Formula Manufacturing Tax Subsidy

Your members of Congress

Enter a ZIP to see where your representative and both senators stood on this bill.

Looked up on this device — your ZIP is never stored on our servers.

What it does

This bill creates two federal tax credits to incentivize domestic infant formula manufacturing: a 30% investment credit (up to $150M per project, $750M total) for companies building or expanding formula plants, and a $2-per-pound production credit (capped at 18 million pounds annually) for companies selling domestically-made formula in the US. Both credits are limited to companies with less than $750M in annual revenue and sunset after 10 years; the credits are transferable and can be paid out directly by the Treasury.

Why we flagged it

The bill's operative mechanism is a direct tax credit—a subsidy—to private infant formula manufacturers. While framed as addressing supply resilience, the credits are unconditional on price, affordability, or public benefit; they are structured as pure production and capital incentives.

What the text implies

  • The $2-per-pound production credit creates an incentive to maximize volume, not quality or affordability; manufacturers have no obligation to pass savings to consumers, and the credit may simply increase manufacturer profit margins.
  • Transferability of credits (via Section 6418) allows manufacturers to sell unused credits to other corporations, creating a secondary tax-credit market that decouples the subsidy from actual formula production and may benefit financial intermediaries.

The full analysis lists 5 implications of this text.

Who stands to gain

infant formula manufacturers (domestic); private equity / investment firms (via credit transferability); tax credit brokers and financial intermediaries

Correlative observation from public records — not evidence of coordination or wrongdoing, and not financial advice.
This page is the record as of today. The app tells you when it changes.
Quorum analysis of the full bill text · 119th Congress · public record